Heart failure & cardiomyopathiesMeta-analysis

Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency

Nat MedPublished

  • Systematic review and meta-analysis of randomised trials
  • Bayesian
  • individual participant data from five trials

Authors' conclusion

These findings suggest that treating iron deficiency in patients with HF significantly reduces cardiovascular events

Study context

Population
Patients with heart failure (HF) and iron deficiency
Participants
7,175 patients · 6 trials
Comparison
IV iron vs placebo
Outcome
Composite of:
  • Recurrent HF hospitalizations
  • CV mortality
Follow-up
12 months

Pooled result

Recurrent HF hospitalizations and CV mortality

Relative risk

0.72

95% CI 0.55–0.89

IV iron vs Placebo
RR 0.72 (95% CI 0.55–0.89)

As reported in the abstract

Further pooled results

OutcomeEstimate
Recurrent HF hospitalizations and CV mortality · complete length of follow-upRR 0.81 (95% CI 0.63–0.97)
Recurrent HF hospitalizations · 12 months and complete length of follow-up — IV iron vs PlaceboRR 0.69 (95% CI 0.48–0.88)
Recurrent HF hospitalizations · 12 months and complete length of follow-up — IV iron vs Placebo · complete follow-upRR 0.78 (95% CI 0.55–0.98)
CV mortality · 12 months and complete length of follow-up — IV iron vs PlaceboHR 0.80 (95% CI 0.61–1.03)
CV mortality · 12 months and complete length of follow-up — IV iron vs Placebo · complete follow-upHR 0.87 (95% CI 0.73–1.04)
All-cause mortality · 12 months and complete length of follow-up — IV iron vs PlaceboHR 0.82 (95% CI 0.65–1.03)
All-cause mortality · 12 months and complete length of follow-up — IV iron vs Placebo · complete follow-upHR 0.92 (95% CI 0.80–1.07)

Original publication

Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. Published 30 March 2025. doi:10.1038/s41591-025-03671-1

Summarised from the published abstract; every number is checked against it